XML 107 R67.htm IDEA: XBRL DOCUMENT v3.8.0.1
Subsequent Event - Additional Information (Detail) - Kite Pharma, Inc. ("Kite") [Member] - Collaboration and License Agreement [Member] - Subsequent Event [Member]
1 Months Ended
Feb. 28, 2018
USD ($)
Subsequent Event [Line Items]  
Milestone revenue receivable $ 150,000,000
Maximum [Member]  
Subsequent Event [Line Items]  
Contingent development - and sales-based milestone payments to be received 3,010,000,000
Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones [Member]  
Subsequent Event [Line Items]  
Contingent development - and sales-based milestone payments to be received 1,260,000,000
Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels [Member]  
Subsequent Event [Line Items]  
Contingent development - and sales-based milestone payments to be received $ 1,750,000,000